Atlas Trials

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.

Clinical trial NCT02663752 · TERMINATED

Trial details

NCT number
NCT02663752
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndrome
Start date
2016-05-30
Primary completion
2016-07-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.